<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00273364</url>
  </required_header>
  <id_info>
    <org_study_id>DI MS.Randomized2004</org_study_id>
    <nct_id>NCT00273364</nct_id>
    <nct_alias>NCT03133403</nct_alias>
  </id_info>
  <brief_title>Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study</brief_title>
  <official_title>Hematopoietic Stem Cell Therapy for Patients With Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy: A Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Uppsala University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sheffield Teaching Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multiple sclerosis (MS) is at onset an immune-mediated demyelinating disease. In most cases,&#xD;
      it starts as a relapsing-remitting disease with distinct attacks and no symptoms between&#xD;
      flares. Over years or decades, virtually all cases transition into a progressive disease in&#xD;
      which insidious and slow neurologic deterioration occurs with or without acute flares.&#xD;
      Relapsing-remitting disease is often responsive to immune suppressive or modulating&#xD;
      therapies, while immune based therapies are generally ineffective in patients with a&#xD;
      progressive clinical course. This clinical course and response to immune suppression, as well&#xD;
      as neuropathology and neuroimaging studies, suggest that disease progression is associated&#xD;
      with axonal atrophy. Disability correlates better with measures of axonal atrophy than immune&#xD;
      mediated demyelination. Therefore, immune based therapies, in order to be effective, need to&#xD;
      be started early in the disease course while MS is predominately an immune-mediated and&#xD;
      inflammatory disease. While current immune based therapies delay disability, no intervention&#xD;
      has been proven to prevent progressive disability. We propose, as a randomized study,&#xD;
      autologous unmanipulated PBSCT using a conditioning regimen of cyclophosphamide and rabbit&#xD;
      antithymocyte globulin (rATG) versus FDA approved standard of care (i.e. interferon,&#xD;
      glatiramer acetate, mitoxantrone, natalizumab, fingolimod, or tecfidera) in patients with&#xD;
      inflammatory (relapsing) MS despite treatment with alternate approved therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the efficacy of autologous PBSCT versus FDA approved standard of care ( i.e.&#xD;
      interferon, glatiramer acetate, mitoxantrone, natalizumab, fingolimod, or tecfidera) for&#xD;
      inflammatory multiple sclerosis (MS) failing failing alternate approved therapy. The&#xD;
      endpoints to be considered in this study are:&#xD;
&#xD;
      2.1 Primary Endpoint:&#xD;
&#xD;
      Disease progression, defined as a 1 point increase in the Expanded Disability Status Scale&#xD;
      (EDSS) on consecutive evaluations at least 6 months apart and not due to a non-MS disease&#xD;
      process. Patients will be followed for 5 years after randomization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 16, 2005</start_date>
  <completion_date type="Actual">August 30, 2019</completion_date>
  <primary_completion_date type="Actual">January 5, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Expanded Disability Status Scale (EDSS) Improvement</measure>
    <time_frame>Pre Treatment, 6 and 12 months Post Treatment</time_frame>
    <description>The EDSS scale ranges from 0 to 10 in 0.5 increments that represent higher levels of disability. Improvement in EDSS is defined by both a 0.5 or 1.0 points sustained for more than 6 months.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with Cyclophosphamide and rATG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard therapy for MS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard treatment with a conventional drug is the treatment with one of the following drugs: Avonex (interferon beta 1a), Betaseron (interferon beta 1b), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Tysabri (natalizumab), Gilenya (fingolimod) or Dimethyl fumarate (Tecfidera or BG-12)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hematopoietic Stem Cell Therapy</intervention_name>
    <description>After mobilization and harvest of stem cells, stem cells will be infused following conditioning regimen</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <other_name>stem cell infusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard treatment with a conventional drug</intervention_name>
    <description>Standard treatment with a conventional drug is the treatment with one of the following drugs: Avonex (interferon beta 1a), Betaseron (interferon beta 1b), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Tysabri (natalizumab), or Gilenya (fingolimod)</description>
    <arm_group_label>Standard therapy for MS</arm_group_label>
    <other_name>standard of care</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age between18-55, inclusive.&#xD;
&#xD;
          2. Diagnosis of MS using revised McDonald criteria of clinically definite MS (Appendix&#xD;
             I).&#xD;
&#xD;
          3. An EDSS score of 2.0 to 6.0 (Appendix II).&#xD;
&#xD;
          4. Inflammatory disease despite treatment with standard disease modifying therapy&#xD;
             including at least 6 months of interferon or copaxone. Inflammatory disease is defined&#xD;
             based on both MRI (gadolinium enhancing lesions) and clinical activity (acute relapses&#xD;
             *treated with IV or oral high dose corticosteroids and prescribed by a neurologist).&#xD;
             Minimum disease activity required for failure is defined as: a) two or more *steroid&#xD;
             treated clinical relapses with documented new objective signs on neurological&#xD;
             examination documented by a neurologist within the year prior to the study, or b) one&#xD;
             *steroid treated clinical relapse within the year prior to study and evidence on MRI&#xD;
             of active inflammation (i.e., gadolinium enhancement) within the last 12 months on an&#xD;
             occasion separate from the clinical relapse (3 months before or after the clinical&#xD;
             relapse).&#xD;
&#xD;
               -  A steroid treated relapse will include a relapse that was severe enough to&#xD;
                  justify treatment but due to patient intolerance of steroids, or a history of&#xD;
                  non-response to steroids, they were offered but not used.&#xD;
&#xD;
        Exclusion Criteria**&#xD;
&#xD;
          1. Any illness that in the opinion of the investigators would jeopardize the ability of&#xD;
             the patient to tolerate aggressive chemotherapy.&#xD;
&#xD;
          2. Prior history of malignancy except localized basal cell, squamous skin cancer or&#xD;
             carcinoma in situ of the cervix. Other malignancies for which the patient is judged to&#xD;
             be cured, such as head and neck cancer, or breast cancer will be considered on an&#xD;
             individual basis.&#xD;
&#xD;
          3. Positive pregnancy test&#xD;
&#xD;
          4. Inability or unwillingness to pursue effective means of birth control from the time of&#xD;
             evaluation for eligibility until 6 months posttransplant (if on transplant) or until&#xD;
             appropriate for non-transplant treatment (if on control arm). Effective birth control&#xD;
             is defined as 1) abstinence defined as refraining from all acts of vaginal&#xD;
             intercourse; 2) consistent use of birth control pills; 3) injectable birth control&#xD;
             methods (Depo-provera, Norplant); 4) tubal sterilization or male partner who has&#xD;
             undergone vasectomy; 5) placement of an intrauterine device (IUD); or 6) use, with&#xD;
             every act of intercourse, of diaphragm with contraceptive jelly and/or condoms with&#xD;
             contraceptive foam.&#xD;
&#xD;
          5. Failure to willingly accept or comprehend irreversible sterility as a side effect of&#xD;
             therapy&#xD;
&#xD;
          6. Forced expiratory volume at one second (FEV1) / forced vital capacity (FVC) &lt; 60% of&#xD;
             predicted after bronchodilator therapy (if necessary)&#xD;
&#xD;
          7. Diffusing capacity of lung for carbon monoxide (DLCO) &lt; 50% of predicted (for the&#xD;
             transplant arm)&#xD;
&#xD;
          8. Resting left ventricular ejection fraction (LVEF) &lt; 50 %&#xD;
&#xD;
          9. Bilirubin &gt; 2.0 mg/dl&#xD;
&#xD;
         10. Serum creatinine &gt; 2.0 mg/dl&#xD;
&#xD;
         11. Known hypersensitivity to mouse, rabbit, or E. Coli derived proteins, or to iron&#xD;
             compounds/medications&#xD;
&#xD;
         12. Presence of metallic objects implanted in the body that would preclude the ability of&#xD;
             the patient to safely have MRI exams&#xD;
&#xD;
         13. Diagnosis of primary progressive MS&#xD;
&#xD;
         14. Diagnosis of secondary progressive MS&#xD;
&#xD;
         15. Platelet count &lt; 100,000/ul, white blood cell count (WBC) &lt; 1,500 cells/mm3&#xD;
&#xD;
         16. Psychiatric illness, mental deficiency or cognitive dysfunction making compliance with&#xD;
             treatment or informed consent impossible&#xD;
&#xD;
         17. Active infection except asymptomatic bacteriuria&#xD;
&#xD;
         18. Use of natalizumab (Tysabri) within the previous 6 months&#xD;
&#xD;
         19. Use of fingolimod (Gilenya) within the previous 3 months&#xD;
&#xD;
         20. Use of teriflunomide (Aubagio) within the previous 2 years unless cleared from the&#xD;
             body (plasma concentration &lt; 0.02mcg/ml) following elimination from the body with&#xD;
             cholestyramine 8g three times a day for 11 days&#xD;
&#xD;
         21. Prior treatment with CAMPATH (alemtuzumab)&#xD;
&#xD;
         22. Prior treatment with mitoxantrone&#xD;
&#xD;
         23. Any hereditary neurological disease such as Charcot-Marie-Tooth disease (CMT) or&#xD;
             Spinocerebellar ataxia (SCA) are contraindications&#xD;
&#xD;
         24. Use of tecfidera within the previous 3 months&#xD;
&#xD;
               -  For patients who clearly have inflammatory disease, an exception can be made if&#xD;
                  agreed upon by study PI and at least two study neurologists.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Burt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University, Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://jamanetwork.com/journals/jama/fullarticle/2720728</url>
    <description>JAMA 2019 MIST</description>
  </link>
  <results_reference>
    <citation>Burt RK, Balabanov R, Burman J, Sharrack B, Snowden JA, Oliveira MC, Fagius J, Rose J, Nelson F, Barreira AA, Carlson K, Han X, Moraes D, Morgan A, Quigley K, Yaung K, Buckley R, Alldredge C, Clendenan A, Calvario MA, Henry J, Jovanovic B, Helenowski IB. Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. JAMA. 2019 Jan 15;321(2):165-174. doi: 10.1001/jama.2018.18743.</citation>
    <PMID>30644983</PMID>
  </results_reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>January 5, 2006</study_first_submitted>
  <study_first_submitted_qc>January 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2006</study_first_posted>
  <results_first_submitted>July 15, 2020</results_first_submitted>
  <results_first_submitted_qc>August 10, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 12, 2020</results_first_posted>
  <last_update_submitted>August 10, 2020</last_update_submitted>
  <last_update_submitted_qc>August 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Richard Burt, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>stem cell, autoimmune disease, multiple sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Hematopoietic Stem Cell Transplantation</title>
          <description>Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with Cyclophosphamide and rATG&#xD;
Hematopoietic Stem Cell Therapy: After mobilization and harvest of stem cells, stem cells will be infused following conditioning regimen</description>
        </group>
        <group group_id="P2">
          <title>Standard Therapy for MS</title>
          <description>Standard treatment with a conventional drug is the treatment with one of the following drugs: Avonex (interferon beta 1a), Betaseron (interferon beta 1b), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Tysabri (natalizumab), Gilenya (fingolimod) or Dimethyl fumarate (Tecfidera or BG-12)&#xD;
Standard treatment with a conventional drug: Standard treatment with a conventional drug is the treatment with one of the following drugs: Avonex (interferon beta 1a), Betaseron (interferon beta 1b), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Tysabri (natalizumab), or Gilenya (fingolimod)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hematopoietic Stem Cell Transplantation</title>
          <description>Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with Cyclophosphamide and rATG&#xD;
Hematopoietic Stem Cell Therapy: After mobilization and harvest of stem cells, stem cells will be infused following conditioning regimen</description>
        </group>
        <group group_id="B2">
          <title>Standard Therapy for MS</title>
          <description>Standard treatment with a conventional drug is the treatment with one of the following drugs: Avonex (interferon beta 1a), Betaseron (interferon beta 1b), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Tysabri (natalizumab), Gilenya (fingolimod) or Dimethyl fumarate (Tecfidera or BG-12)&#xD;
Standard treatment with a conventional drug: Standard treatment with a conventional drug is the treatment with one of the following drugs: Avonex (interferon beta 1a), Betaseron (interferon beta 1b), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Tysabri (natalizumab), or Gilenya (fingolimod)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="55"/>
            <count group_id="B2" value="55"/>
            <count group_id="B3" value="110"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="55"/>
                    <count group_id="B2" value="55"/>
                    <count group_id="B3" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.6" lower_limit="18" upper_limit="54"/>
                    <measurement group_id="B2" value="35.6" lower_limit="19" upper_limit="52"/>
                    <measurement group_id="B3" value="35.6" lower_limit="18" upper_limit="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="55"/>
                    <count group_id="B2" value="55"/>
                    <count group_id="B3" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Expanded Disability Status Scale (EDSS)</title>
          <description>The EDSS provides a total disability score on a scale that ranges from 0 (no disability) to 10 (worst neurologic disability).</description>
          <population>The number analyzed in rows differs from the overall enrolled because EDSS were not analyzed on patients who did not receive intervention or who were lost to follow up.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="54"/>
                    <count group_id="B3" value="106"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.4" spread="1.2"/>
                    <measurement group_id="B2" value="3.3" spread="1.0"/>
                    <measurement group_id="B3" value="3.35" spread=".05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Expanded Disability Status Scale (EDSS) Improvement</title>
        <description>The EDSS scale ranges from 0 to 10 in 0.5 increments that represent higher levels of disability. Improvement in EDSS is defined by both a 0.5 or 1.0 points sustained for more than 6 months.</description>
        <time_frame>Pre Treatment, 6 and 12 months Post Treatment</time_frame>
        <population>The number analyzed in one or more rows differs from the overall number analyzed because not all patients had their EDSS evaluated and some patients were lost to followed up.</population>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplantation</title>
            <description>Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with Cyclophosphamide and rATG&#xD;
Hematopoietic Stem Cell Therapy: After mobilization and harvest of stem cells, stem cells will be infused following conditioning regimen</description>
          </group>
          <group group_id="O2">
            <title>Standard Therapy for MS</title>
            <description>Standard treatment with a conventional drug is the treatment with one of the following drugs: Avonex (interferon beta 1a), Betaseron (interferon beta 1b), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Tysabri (natalizumab), Gilenya (fingolimod) or Dimethyl fumarate (Tecfidera or BG-12)&#xD;
Standard treatment with a conventional drug: Standard treatment with a conventional drug is the treatment with one of the following drugs: Avonex (interferon beta 1a), Betaseron (interferon beta 1b), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Tysabri (natalizumab), or Gilenya (fingolimod)</description>
          </group>
        </group_list>
        <measure>
          <title>Expanded Disability Status Scale (EDSS) Improvement</title>
          <description>The EDSS scale ranges from 0 to 10 in 0.5 increments that represent higher levels of disability. Improvement in EDSS is defined by both a 0.5 or 1.0 points sustained for more than 6 months.</description>
          <population>The number analyzed in one or more rows differs from the overall number analyzed because not all patients had their EDSS evaluated and some patients were lost to followed up.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre Treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="1.2"/>
                    <measurement group_id="O2" value="3.3" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Months Post Treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="1.4"/>
                    <measurement group_id="O2" value="3.7" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Months Post Treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="1.4"/>
                    <measurement group_id="O2" value="4" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected during transplant and at 1 year post Treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Hematopoietic Stem Cell Transplantation</title>
          <description>Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with Cyclophosphamide and rATG&#xD;
Hematopoietic Stem Cell Therapy: After mobilization and harvest of stem cells, stem cells will be infused following conditioning regimen</description>
        </group>
        <group group_id="E2">
          <title>Standard Therapy for MS</title>
          <description>Standard treatment with a conventional drug is the treatment with one of the following drugs: Avonex (interferon beta 1a), Betaseron (interferon beta 1b), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Tysabri (natalizumab), Gilenya (fingolimod) or Dimethyl fumarate (Tecfidera or BG-12)&#xD;
Standard treatment with a conventional drug: Standard treatment with a conventional drug is the treatment with one of the following drugs: Avonex (interferon beta 1a), Betaseron (interferon beta 1b), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Tysabri (natalizumab), or Gilenya (fingolimod)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile Neutropenia (culture negative)</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Hypergylcemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limitations to the study are the relatively small number of patients who were treated compared with pharmaceutical sponsored trials, and the relatively small sample size resulted in small numbers of patients available to assess longer term outcomes.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Kathleen Quigley</name_or_title>
      <organization>Northwestern University</organization>
      <phone>312-695-8192</phone>
      <email>k-quigley@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

